CPI Patient Safety & Risk Management 2 — Questions and Answers
Question 1: A root cause analysis (RCA) of a medication error in a clinical trial reveals that a nurse administered the wrong dose because of an illegible handwritten order. What is the MOST appropriate systemic corrective action?
- Retrain the nurse on medication administration
- Implement electronic order entry to eliminate handwritten prescriptions (Correct answer)
- Suspend the nurse pending investigation
- Add a second nurse to verify all orders
Correct answer: Implement electronic order entry to eliminate handwritten prescriptions
Systemic solutions such as electronic order entry address the root cause by eliminating illegible handwriting rather than placing blame on individuals.
Question 2: Under ICH E6(R2) guidelines, what is the principal investigator's responsibility when a serious adverse event (SAE) occurs in a clinical trial?
- Report the SAE to the FDA within 7 calendar days
- Notify the sponsor immediately and complete required documentation (Correct answer)
- Discontinue the participant from the study
- Convene an independent data safety monitoring board
Correct answer: Notify the sponsor immediately and complete required documentation
ICH E6(R2) requires the PI to promptly notify the sponsor of SAEs so the sponsor can fulfill regulatory reporting obligations.
Question 3: A participant in a drug trial develops an unexpected anaphylactic reaction. After stabilizing the patient, what is the FIRST documentation step the investigator should take?
- Update the protocol to exclude participants at risk
- Complete an SAE report form documenting the event details (Correct answer)
- Notify the IRB before documenting in the source record
- Wait for the event to resolve before documenting
Correct answer: Complete an SAE report form documenting the event details
Timely and accurate documentation in the SAE report form is the first required step after ensuring participant safety.
Question 4: Which strategy is MOST effective in reducing protocol deviations related to patient safety in clinical trials?
- Increasing participant stipends to improve adherence
- Providing comprehensive staff training and protocol-specific procedures (Correct answer)
- Reducing the number of study visits
- Delegating safety monitoring to a central lab
Correct answer: Providing comprehensive staff training and protocol-specific procedures
Comprehensive staff training and clear SOPs reduce misunderstandings that lead to protocol deviations affecting safety.
Question 5: In a clinical trial, a near-miss event occurs when a pharmacist catches a wrong-drug dispensing error before the participant receives it. What should be done with this near-miss?
- Ignore it since no harm occurred
- Document and report it through the site's safety reporting system (Correct answer)
- Report it only if it happens again
- Inform the participant and withdraw them from the study
Correct answer: Document and report it through the site's safety reporting system
Near-misses must be documented and analyzed because they reveal latent system failures that can lead to future harm.
Question 6: A clinical trial participant who is enrolled in a study on an experimental anticoagulant is scheduled for an elective dental procedure. What is the investigator's primary responsibility?
- Withdraw the participant from the study before the procedure
- Coordinate communication between the dentist and the study team regarding investigational drug interactions (Correct answer)
- Suspend the investigational drug without informing the sponsor
- Refer the participant back to their primary care physician only
Correct answer: Coordinate communication between the dentist and the study team regarding investigational drug interactions
The investigator must facilitate communication between treating providers to ensure safe management of concomitant procedures involving investigational agents.
Question 7: What is the purpose of a Data Safety Monitoring Board (DSMB) in a clinical trial?
- To approve all protocol amendments before they take effect
- To independently review accumulating safety and efficacy data and recommend stopping or modifying the trial if necessary (Correct answer)
- To adjudicate all adverse events reported by the investigator
- To ensure regulatory submissions are filed on time
Correct answer: To independently review accumulating safety and efficacy data and recommend stopping or modifying the trial if necessary
The DSMB serves as an independent oversight body that can recommend trial modification or termination based on interim safety and efficacy reviews.
CPI Patient Safety & Risk Management 2
A root cause analysis (RCA) of a medication error in a clinical trial reveals that a nurse administered the wrong dose because of an illegible handwritten order.
What is the MOST appropriate systemic corrective action?